Search companies

Live

Tuesday, 17 November 2026 · 578 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Cambium Bio advances Phase 3 preparations as trial start remains gated by CRO contracts

CMB: $0.420 +0.00% · MC: $11M

Cambium Bio submitted an updated CAMOMILE-2 Phase 3 protocol to the FDA, and manufacturing has progressed to a technical batch, with an engineering batch under way and the first clinical batch scheduled for November. However, CRO agreements remain unsigned and are now targeted for completion in the fourth quarter, a key step before site activation and the first patient; the company reported approximately $1 million in cash at quarter-end and a further $4 million in total available funding including an undrawn facility. A conditional placement of approximately $7 million is subject to shareholder approval at the November AGM.

Source announcements: 2026-10-28 18:37 to 2026-10-28 18:37 Sydney time
Story updated 2026-10-28 18:40 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments